Q: Cipher's quarterly report highlights transitions and strategic positioning for long term growth, also debt reduction. Their list of 2018 year end highlights appears impressive but does it read that way to you? This company looks busy for their size but what significants do you take from the list of 2019 anticipated milestones? Would you dip a toe in here? Finally how similar are CPH and GUD in strategic growth plans?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Opinion of value after last report, and responding share price movement?
Q: What is the outlook for CRMD ? I am 21% under water. Hold, sell, buy more ?Thank you for the good work.
Jacques
Jacques
Q: Celgene appears to be stumbling higher, presumably towards the value assigned to it from the Bristol Myers merger. In past months, you previously suggested holding on; is that still your view? Also, can you suggest a source for information on the tax treatment from the merger for Canadian taxpayers who hold Celgene? Thanks,
Q: Any idea why TH has been so weak lately. I know sales have been short of expectations for their new life saving drug but they are still rising slowly. Also their older drug Egrifta may have some benefits for people with NAFLD/NASH. Balance sheet is good.
Should one buy here?
Should one buy here?
Q: Could I get your thoughts on how HHL might behave in a recession. I understand Healthcare as a sector would be a Defensive sector however I also understand 5i is not to crazy about the cover call aspect, believing it would not protect again the down side. So how would HHL behave? Would the price fall greater than the average defensive share price, or would investors still consider it a defensive play and hold steady the price. Or would the cover call aspect cease to work and the dividends reduce? If it's more an impact on the dividends, is there a way of telling how much the
cover calling is adding to the dividends and therefore what dividends could be expected in times of a recession. Thanks
cover calling is adding to the dividends and therefore what dividends could be expected in times of a recession. Thanks
Q: How much cash/share does Knight Therapeutics have? Thanks.
Q: Theratechnologies was at $9.35 on Feb 28th and it closed on Mar 15th at $6.99. The recent press releases all seem favorable to me. Why is this stock down so dramatically?
Q: I'm wondering if you could share any thoughts you have on TEVA. I have a small position, but it's been a frustrating hold. Thanks.
Q: To add to what Steven comment today on the Company. I respect M. Goodman view on the long term goals of the company. His analogy for is "grandchildren" and stockholders would make sense if at the very least a dividend would be paid for waiting.
This would a small way to compensate to the shareholders while we are supporting the company.
This would a small way to compensate to the shareholders while we are supporting the company.
Q: what exactly is medison fighting for and how much of a lock does goodman have on knight.
dave
dave
Q: High volume at the close. My guess is insiders did the buying, if so how many days before they have to disclose ?
Also I noticed that for my last 2 questions I did not receive the answer by email but saw the answer on your site. Has something changed ?
Thanks for your help.
Also I noticed that for my last 2 questions I did not receive the answer by email but saw the answer on your site. Has something changed ?
Thanks for your help.
Q: Hi 5i,
I saw your first two references to this stock on Friday and both were positive. Could you give me your take on its potential and risks?
TIA!
I saw your first two references to this stock on Friday and both were positive. Could you give me your take on its potential and risks?
TIA!
Q: Hi. Any news on what happened with GUD in the last 20 minutes? Thanks
Q: In response to a question about a subscriber's portfolio you said “KO and JNJ we would consider less attractive for various reasons. We might add VZ and PFE instead.”. I am holding JNJ in a non-registered account with a cost base of $58.36/share. JNJ is 2.5% of a diversified portfolio. Is it still worth making the switch for PFE? Over the years, JNJ seemed to be a much better managed company than PFE. What has changed?
-
Knight Therapeutics Inc. (GUD $7.55)
-
BMO Equal Weight US Health Care Hedged to CAD Index ETF (ZUH $65.50)
Q: I have very little in the health care industry, I only own GUD at 1.5% of my portfolio. I am thinking of selling GUD and buying ZUH at say 2.5% of my portfolio. Your thoughts please. Or would you suggest some other health ETF?
-
Illumina Inc. (ILMN $135.78)
-
Intuitive Surgical Inc. (ISRG $457.78)
-
Guardant Health Inc. (GH $87.60)
Q: Could I please get your top 3 growth stocks in the medical technology sector, USA, for a long term hold, in order of preference. Thanks
Q: In response to a recent question about GUD, you mentioned that "there is an unhappy shareholder and board member who wants some changes made at the company". Could you please provide more detail about why he/she is unhappy and what changes they would like to be made? Thank you.
Q: Can you comment on the quarter and what you think of the company moving forward?
Q: Not a question just a statement. Here is a reminder for us long term holders of Knight Therapeutics on what the investment horizon may be.
"For investors, if their investment horizon is not their grandchildren, we are not the right company for them. Paladin had 19 years of record revenues but for 12 of those years, our stock was flat. It took us 19 years to become an overnight success." - Jonathan Ross Goodman
"For investors, if their investment horizon is not their grandchildren, we are not the right company for them. Paladin had 19 years of record revenues but for 12 of those years, our stock was flat. It took us 19 years to become an overnight success." - Jonathan Ross Goodman